NCT07102056Not yet recruiting
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms
Source: ClinicalTrials.gov · Last updated 29 Dec 2025
Brief summary (registry, in English)
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 152 (estimated)
- First submitted
- 8 Jul 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 3 Jun 2027
- Lead sponsor
- First Affiliated Hospital of Zhejiang University
- Diseases
- Neuroendocrine tumours
- NCT number
- NCT07102056
What you commit to
- Study type: Observational
- Planned participants: 152
- From 1 Jan 2026 to the primary completion date, 3 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Inability to undergo biopsy/surgical treatment.
- Concurrent active malignancy.
Other illness
- Severe uncontrolled comorbidities/active infections.
Other
- Inability to provide informed consent.
Who the study is looking for
- Clinical diagnosed of neuroendocrine neoplasms.
- Suspected of neuroendocrine neoplasms.
Age in the registry: 20 years to 80 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.